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Introduction
Renal transplant is the most desired and cost-effective therapy for
patients with end stage renal disease. While a lower urinary tract cause
of end-stage renal disease (ESRD) is not an absolute contraindication to
renal transplantation, appropriate vesical storage and drainage is im-
perative for survival and function of the graft.1 It is crucial to address
and resolve any urological causes of renal failure prior to transplanta-
tion to prevent subsequent graft failure. Most patients can be managed
with conservative measures such as intermittent self-catheterization,
but select cases may require more aggressive intervention including
bladder augmentation or urinary diversion to address a hostile bladder
environment prior to transplantation.1 To our knowledge, this is the
first report of a poorly compliant bladder noted during pre-transplant
evaluation that was managed conservatively with intravesical botu-
linum injections leading to a successful transplantation.
Case presentations
The patient is a 22-year-old female in ESRD with a history of neu-
rogenic bladder of unknown etiology characterized by elevated bladder
storage pressures and urinary incontinence. Her history is also sig-
nificant for recurrent UTIs during her childhood and progressive diffi-
culty with voiding. At the age of 11, the patient started dialysis and
began performing clean intermittent catheterization (CIC) four times
daily with spontaneous intermittent incontinence. She had previous
intravesical botulinum toxin injections as an adolescent to reduce her
bladder pressures. At the time of initial evaluation, she was on oxy-
butynin 15mg XL daily and had not seen a urologist for over two years.
Her pre-transplant urologic evaluation included voiding cystoure-
throgram (VCUG), cystoscopy, urodynamics (UDS) and MRI of the
lumbar and sacral spine. The VCUG revealed no vesicoureteral reflux.
Cystoscopic evaluation revealed a small and trabeculated bladder. UDS
noted a small capacity bladder with poor compliance and elevated
storage pressures (Fig. 1). The patient was unable to void during the
study despite receiving permission. MRI of the lumbar and sacral spine
did not reveal canal or foraminal stenosis. Given the low bladder ca-
pacity, unsafe storage pressures, and the patient's reluctancy to undergo
any major operations, recommendation was made for intravesical bo-
tulinum toxin injections (300U) and CIC every three hours. The patient
reported improvement in urgency between catheterizations after her
first intravesical botulinum toxin injection. Following her second in-
jection six months later, a repeat UDS revealed significant improvement
of bladder function with increased capacity and normalization of
compliance and storage pressures (Fig. 2). The decision was made to
continue the scheduled injections instead of pursuing a more aggressive
option to manage her elevated storage pressures. She went on to receive
a renal transplant after her 6th intravesical botulinum toxin injection
and continues to have optimal graft function with scheduled injections
every six months and CIC.
Discussion
The success of a renal transplant depends on many factors. From a
urologic perspective, the lower urinary tract should be sterile, con-
tinent, compliant, with adequate capacity and without bladder outlet
obstruction.2 Optimal bladder compliance and capacity are imperative
for graft survival as it is well-established that elevated detrusor leak
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point pressures in neurogenic bladders is associated with upper tract
deterioration.3 When a poorly compliant bladder is encountered in the
pre-transplant setting, steps must be taken to create a low pressure
reservoir that can be emptied in a safe and repeatable method before
proceeding with renal transplantation.
Traditionally, poorly compliant bladders have been managed with
anticholinergics and CIC, bladder augmentation or urinary diversion.
Bladder augmentation has historically been the gold standard for
management of anti-cholinergic refractory, poorly compliant bladders
because it reliably increases bladder capacity and improves compliance
to maintain safe storage pressures. Alternatively, urinary diversion
bypasses the dysfunctional or non-compliant reservoir. However, these
major surgical operations carry significant short-term and long-term
complications including mucus production, bladder stones, electrolyte
abnormalities and bladder perforation.4 The advent of intravesical bo-
tulinum has provided an alternative non-surgical management option
to improve bladder compliance when more conservative methods have
failed.
Intravesical botulinum injections can significantly increase bladder
capacity, improve compliance and decrease detrusor overactivity and
urge incontinence in patients with neurogenic bladders.5 As a mini-
mally invasive treatment alternative, it spares or potentially delays
patients from morbidities and mortalities associated with more invasive
surgical options. While these advantages make intravesical botulinum
an attractive alternative to bladder augmentation and urinary diver-
sion, we must be cognizant of the need for repeated botulinum injec-
tions since the effect of the toxin eventually wears off. This is un-
deniably one of the biggest disadvantages of the therapy as it subjects
patients to repeated risks associated with the procedure and anesthesia.
Patients may overlook the risks and inconvenience of receiving re-
peated injections indefinitely due to the desire to preserve their native
bladder, which was the preference of our patient. These patients must
be carefully counseled on the importance of routine follow-up and have
a clear understanding that their bladder dynamics may change over
Fig. 1. Urodynamic study performed at initial evaluation prior to initiation of intravesical botulinum toxin injections. The study demonstrated a poorly compliant
bladder with a capacity of 201mL and maximum storage pressure of 52cm H2O. The patient was unable to void during this study.
Fig. 2. Urodynamic study performed after the second intravesical botulinum injection, which revealed improved capacity to 331mL, and normalization of com-
pliance and storage pressures. Like the first study, the patient was unable to void despite permission to do so.
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time even with scheduled injections, and that if their bladder para-
meters no longer respond to intravesical botulinum toxin injections
then a more aggressive surgical management options may need to be
pursued. The described case of a hostile bladder optimized in the pre-
transplant setting with intravesical botulinum injections, ultimately
leading to successful renal transplantation without surgical intervention
of the lower urinary tract demonstrates utility of botulinum toxin in this
patient population. While the long-term benefits of botulinum toxin in
this setting is yet to be determined, we believe that this management
strategy warrants further evaluation.
Conclusion
We found through our experience that intravesical botulinum in-
jections offers a conservative approach to increase bladder compliance
and lower storage pressures thereby permitting safe renal transplanta-
tion. This management strategy can be employed in carefully selected
patients who have failed oral anticholinergics and CIC, and wish to
avoid bladder augmentation and urinary diversion. Careful follow-up is
necessary to detect changes in urinary symptoms and bladder para-
meters, which may be a sign of possible botulinum failure necessitating
the need to revisit more aggressive management options.
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